Australian clinical research organisation (CRO) Nucleus Network has selected Labpas CT, from Labpas, to fully automate its Phase 1 clinical trials. It is the sixth high-profile CRO to select the clinical trial software solution in the past year.
Andrew Giddy, CEO of Nucleus Network, claimed that Labpas CT has helped to raise the profile of the CRO in Australia, by increasing the efficiency of clinical trials and providing greater compliance to laboratory regulations.
The software streamlines clinical processes, such as recruitment, reporting and sample storage. It includes a bar code scanner to record collection times and dosage, and an electronic signature system to support FDA 21 CFR Part 11.
Nucleus Network has also volunteered to demonstrate the software on behalf of Labpas to Australian and Asian clients. Other CROs that have chosen the software include Cedra, Acclaim, and Advanced Biomedical Research.